Novan, a Ligand Company, is a medical dermatology organization primarily focused on researching, developing, and commercializing innovative therapeutic products for skin diseases. Our goal is to deliver safe and efficacious therapies to patients, including developing product candidates where there are unmet medical needs.
The U.S. Food and Drug Administration (“FDA”) has accepted Novan’s new drug application (“NDA”) submission for review for berdazimer gel, 10.3% (SB206) as a topical prescription gel for the treatment of molluscum contagiosum. Novan also has a pipeline of potential product candidates using its proprietary nitric oxide-based technology platform, NITRICIL™, to generate new treatments for multiple indications.
On September 27, 2023, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND), through its subsidiary LNHC, Inc., closed a transaction to acquire berdazimer gel, 10.3% (SB206) and the proprietary nitric oxide-based technology platform, NITRICIL™ from Novan, Inc., now known as NVN Liquidation, Inc.
